Phaseline

Companies › Noorik Biopharmaceuticals

Noorik Biopharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 4, 1 Phase 3; Cardiovascular, Gastroenterology, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ambrisentan
Endothelin receptor, ET-A/ET-B antagonist
EDNRB, EDNRAPhase 2Hepatorenal Syndrome; IgA Nephropathy; Pulmonary Arterial Hypertension (PAH)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06256432AmbrisentanPhase 2Hepatorenal SyndromeGastroenterologyMay 2026
NCT07030894AmbrisentanPhase 4IgA NephropathyGenitourinaryDec 2026
NCT07245680AmbrisentanPhase 3Pulmonary Arterial Hypertension (PAH)CardiovascularFeb 2029

Targets

EDNRB (1) EDNRA (1)

Companies with the same targets

Pharmazz Johnson & Johnson (Janssen) Novartis Travere Therapeutics AstraZeneca

Companies built like this

Matrix Biomed Rege Nephro Livzon Pharmaceutical Group Novaliq Neurimmune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.